Introducing State Pharmacy Now — a new digital magazine presented by DSN, NASPA
The Drug Store News Group has partnered with the National Alliance of State Pharmacy Associations to produce State Pharmacy Now, an exciting, new, first-of-its-kind digital magazine and a must-read for pharmacy professionals across the country. Jammed full of informative articles, charts and data, interactive videos, new product reviews in OTC and technology, and leading executive viewpoints on the state of the industry, the premiere edition of State Pharmacy Now features extensive coverage from NACDS Total Store Expo, including Hillary Clinton on the critical role pharmacy will play in health reform, as well as an in-depth look at how medication synchronization is wowing patients and payers, and one pharmacy chain that is racking up improved outcomes and driving script count because of it.
Actavis, Warner Chilcott meet last regulatory requirements for merger
DUBLIN — Ireland’s High Court has approved Actavis’ acquisition of Warner Chilcott, the drug makers said.
The companies said the approval of Irish authorities meant that they had obtained all regulatory approvals required to complete the transaction, and that it now remained subject to satisfaction of other customary closing conditions and would occur as soon as practicable.
Actavis and Warner Chilcott announced the $8.5 billion merger deal in May. The companies’ shareholders voted to approve it on Sept. 10.
Teva launches generic version of AbbVie’s Zemplar
JERUSALEM — Generic drug maker Teva Pharmaceutical Industries has launched a version of a drug used to treat a parathyroid disorder related to kidney disease.
Teva announced Tuesday the launch of paricalcitol, a generic version of AbbVie’s Zemplar. As the first company to win Food and Drug Administration approval for the drug, Teva has 180 days in which to compete directly with the branded version.
The drug is an active form of vitamin D used to prevent and treat secondary hyperparathyroidism, a condition that causes increased parathyroid hormone levels, in aptients with Stage 3 or Stage 4 chronic kidney disease and in Stage 5 patients on dialysis.
Zemplar had sales of about $115 million during the 12-month period that ended in June, according to IMS Health.